Cargando…

The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions

Breast cancer (BC) in elderly women is an increasing health issue due to demographic changes. BC tends to present later and may receive less than standard treatment options. More often, BC in elderly patients is endocrine-positive (HR+). The treatment of elderly patients with metastatic BC (mBC) rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laface, Carmelo, Giuliani, Francesco, Melaccio, Assunta, Pappagallo, Maria Nicla, Santoro, Anna Natalizia, Perrone, Martina, De Santis, Pierluigi, Guarini, Chiara, Carrozzo, Daniela, Fedele, Palma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532156/ https://www.ncbi.nlm.nih.gov/pubmed/37762952 http://dx.doi.org/10.3390/jcm12186012

Ejemplares similares

Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives
por: Maselli, Felicia Maria, et al.
Publicado: (2023)

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
por: Laface, Carmelo, et al.
Publicado: (2023)

Immunotherapy and Pancreatic Cancer: A Lost Challenge?
por: Laface, Carmelo, et al.
Publicado: (2023)

Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
por: Laface, Carmelo, et al.
Publicado: (2022)

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
por: Ria, Roberto, et al.
Publicado: (2020)

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
por: Andrahennadi, Samitha, et al.
Publicado: (2021)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma
por: Castella, Barbara, et al.
Publicado: (2018)

Loco-Regional and Systemic Chemotherapies for Hepato-Pancreatic Tumors: Integrated Treatments
por: Ranieri, Girolamo, et al.
Publicado: (2020)

Clinical Updates for Gastrointestinal Malignancies
por: Laface, Carmelo, et al.
Publicado: (2023)

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
por: Laface, Carmelo, et al.
Publicado: (2023)

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies
por: Ria, Roberto, et al.
Publicado: (2014)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
por: Guarini, Chiara, et al.
Publicado: (2021)

Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies
por: Reale, Antonia, et al.
Publicado: (2016)

The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2019)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

The rate of change in declining steroid hormones: a new parameter of healthy aging in men?
por: Walther, Andreas, et al.
Publicado: (2016)

HER2-Low Breast Cancer: Current Landscape and Future Prospects
por: Shirman, Yelena, et al.
Publicado: (2023)

Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
por: Perrotta, Fabio, et al.
Publicado: (2019)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer
por: Torrisi, Rosalba, et al.
Publicado: (2022)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
por: Chilà, Giovanna, et al.
Publicado: (2021)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
por: Han, Yanjie, et al.
Publicado: (2023)

Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer
por: Zhang, Huina, et al.
Publicado: (2022)

Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
por: Melaccio, Assunta, et al.
Publicado: (2022)

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
por: Garutti, Mattia, et al.
Publicado: (2022)

Role of hormonal risk factors in HER2-positive breast carcinomas
por: Balsari, A, et al.
Publicado: (2003)

Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
por: Shagisultanova, Elena, et al.
Publicado: (2022)

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
por: Sonke, Gabe S., et al.
Publicado: (2017)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

HER2‐positive breast cancer brain metastasis: A new and exciting landscape
por: Zimmer, Alexandra S., et al.
Publicado: (2020)

The Landscape of Actionable Gene Fusions in Colorectal Cancer
por: Pagani, Filippo, et al.
Publicado: (2019)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study
por: Cicco, Sebastiano, et al.
Publicado: (2020)

Prognostic and Therapeutic Role of Angiogenic Microenvironment in Thyroid Cancer
por: Melaccio, Assunta, et al.
Publicado: (2021)

Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
por: Li, Yan, et al.
Publicado: (2022)

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
por: Kim, S T, et al.
Publicado: (2018)

Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors
por: Cusan, Martina, et al.
Publicado: (2018)

Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
por: Staaf, Johan, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lstmd26ngim04470op2vitke3b